Jorey Chernett, Owner of More than 5.5% of Outstanding Shares of CVRx, Calls on Board to Begin Immediate Process to Pursue Sale of the Company to a Strategic Acquirer
Delivers Letter to the CVRx Board Highlighting Significant Value Proposition of Barostim to a Large Medical Device Company with Established Infrastructure to Capitalize on the Product's Market Position
In the letter,
As a result,

- Immediately retain an independent financial advisor and initiate a comprehensive review of strategic alternatives, with a sale of the Company as the priority outcome;
- Aggressively cut executive compensation and G&A expense, as well as suspend incremental standalone spending commitments while that review is conducted; and
- Publicly commit to a comprehensive process and clear timeline. A sale process launched now, while the Company retains cash, momentum in the field, and the strategic scarcity of the only approved neuromodulation therapy for heart failure, will command a far better outcome for shareholders than one forced upon the Company as a result of a depleted cash balance a year from now. The Board must move with urgency instead of waiting to be rescued; time is of the essence.
The full text of the letter is available HERE.
Media Contact:
ASC Advisors
Taylor Ingraham /
[email protected] / [email protected]
203 992 1230
View original content to download multimedia:https://www.prnewswire.com/news-releases/jorey-chernett-owner-of-more-than-5-5-of-outstanding-shares-of-cvrx-calls-on-board-to-begin-immediate-process-to-pursue-sale-of-the-company-to-a-strategic-acquirer-302858259.html
SOURCE

